206 related articles for article (PubMed ID: 1710247)
21. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.
Ohlin M; Broliden PA; Danielsson L; Wahren B; Rosen J; Jondal M; Borrebaeck CA
Immunology; 1989 Nov; 68(3):325-31. PubMed ID: 2480328
[TBL] [Abstract][Full Text] [Related]
22. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.
Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS
J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307
[TBL] [Abstract][Full Text] [Related]
23. An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.
Till M; May RD; Uhr JW; Thorpe PE; Vitetta ES
Cancer Res; 1988 Mar; 48(5):1119-23. PubMed ID: 3257712
[TBL] [Abstract][Full Text] [Related]
24. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
25. Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.
Pincus SH; Wehrly K; Tschachler E; Hayes SF; Buller RS; Reitz M
J Exp Med; 1990 Sep; 172(3):745-57. PubMed ID: 1696955
[TBL] [Abstract][Full Text] [Related]
26. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.
Pincus SH; Song K; Maresh GA; Frank A; Worthylake D; Chung HK; Polacino P; Hamer DH; Coyne CP; Rosenblum MG; Marks JW; Chen G; Weiss D; Ghetie V; Vitetta ES; Robinson JE; Hu SL
J Virol; 2017 Feb; 91(3):. PubMed ID: 27795412
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibody identifies a highly conserved and immunodominant epitope of the human immunodeficiency virus transmembrane protein.
Papsidero LD; Poiesz BJ; Montagna RA
Hybridoma; 1988 Apr; 7(2):117-28. PubMed ID: 2453451
[TBL] [Abstract][Full Text] [Related]
28. Antibody internalization after cell surface antigen binding is critical for immunotoxin development.
Kuo SR; Alfano RW; Frankel AE; Liu JS
Bioconjug Chem; 2009 Oct; 20(10):1975-82. PubMed ID: 19785403
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.
Wawrzynczak EJ; Derbyshire EJ; Henry RV; Parnell GD; Smith A; Waibel R; Stahel RA
Br J Cancer Suppl; 1991 Jun; 14():71-3. PubMed ID: 1645577
[TBL] [Abstract][Full Text] [Related]
30. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.
Pincus SH; Fang H; Wilkinson RA; Marcotte TK; Robinson JE; Olson WC
J Immunol; 2003 Feb; 170(4):2236-41. PubMed ID: 12574398
[TBL] [Abstract][Full Text] [Related]
31. Production and characterization of a human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type I.
Teeuwsen VJ; Siebelink KH; Crush-Stanton S; Swerdlow B; Schalken JJ; Goudsmit J; van de Akker R; Stukart MJ; Uytdehaag FG; Osterhaus AD
AIDS Res Hum Retroviruses; 1990 Mar; 6(3):381-92. PubMed ID: 1692724
[TBL] [Abstract][Full Text] [Related]
32. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
33. Selective killing of HIV-infected cells by anti-gp120 immunotoxins.
Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K
AIDS Res Hum Retroviruses; 1990 Feb; 6(2):193-203. PubMed ID: 2328157
[TBL] [Abstract][Full Text] [Related]
34. AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy.
Pincus SH; Wehrly K
J Infect Dis; 1990 Dec; 162(6):1233-8. PubMed ID: 2230256
[TBL] [Abstract][Full Text] [Related]
35. Selective cytotoxicity of a novel immunotoxin based on pulchellin A chain for cells expressing HIV envelope.
Sadraeian M; Guimarães FEG; Araújo APU; Worthylake DK; LeCour LJ; Pincus SH
Sci Rep; 2017 Aug; 7(1):7579. PubMed ID: 28790381
[TBL] [Abstract][Full Text] [Related]
36. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
Castelletti D; Fracasso G; Righetti S; Tridente G; Schnell R; Engert A; Colombatti M
Clin Exp Immunol; 2004 May; 136(2):365-72. PubMed ID: 15086403
[TBL] [Abstract][Full Text] [Related]
37. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells.
Levin LV; Griffin TW; Childs LR; Davis S; Haagensen DE
Cancer Immunol Immunother; 1987; 24(3):202-6. PubMed ID: 3496151
[TBL] [Abstract][Full Text] [Related]
38. Partial purification of native HIV transmembrane protein gp41: generation of polyclonal and monoclonal antibodies.
Zweig M; Showalter SD; Bladen SV; Gilden RV; Arthur LO; Robey WG; Nara PL; Fischinger PJ
AIDS Res Hum Retroviruses; 1988 Feb; 4(1):51-62. PubMed ID: 3259140
[TBL] [Abstract][Full Text] [Related]
39. Neutralisation of HIV isolates by anti-idiotypic antibodies which mimic the T4 (CD4) epitope: a potential AIDS vaccine.
Dalgleish AG; Thomson BJ; Chanh TC; Malkovsky M; Kennedy RC
Lancet; 1987 Nov; 2(8567):1047-50. PubMed ID: 2444842
[TBL] [Abstract][Full Text] [Related]
40. Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.
Till MA; Ghetie V; May RD; Auerbach PC; Zolla-Pazner S; Gorny MK; Gregory T; Uhr JW; Vitetta ES
J Acquir Immune Defic Syndr (1988); 1990; 3(6):609-14. PubMed ID: 2140127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
